Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions

Abstract

A computational mechanistic viral infection model and trial simulation advocates for adaptation of respiratory disease clinical trials whose chances of success and interpretability are being degraded under COVID-19 pandemic mitigation measures.